Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression

Authors

+9 authors

Journal

Published

Jun 1, 2024

DOI

Save

Tip

Document

Download

Flag content

Tip

Save

Document

Download

Flag content

Abstract

Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.